Initial antifungal strategy does not correlate with mortality in patients with candidemia

• Published in: European journal of clinical microbiology & infectious diseases 2016-02, Vol.35 (2), p.187-193
• Main Authors: Murri, R., Scoppettuolo, G., Ventura, G., Fabbiani, M., Giovannenze, F., Taccari, F., Milozzi, E., Posteraro, B., Sanguinetti, M., Cauda, R., Fantoni, M.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Amphotericin B - therapeutic use; Antifungal Agents - therapeutic use; Biomedical and Life Sciences; Biomedicine; Candida; Candida albicans - isolation & purification; Candida glabrata - isolation & purification; Candidemia - drug therapy; Candidemia - microbiology; Candidemia - mortality; Catheters; Cohort analysis; Cohort Studies; Echinocandins - therapeutic use; Female; Fluconazole - therapeutic use; Fungal Proteins - therapeutic use; Hospitalization; Hospitals; Humans; Infectious diseases; Intensive care; Intensive Care Units; Internal Medicine; Male; Medical Microbiology; Microbial Sensitivity Tests; Middle Aged; Mortality; Original Article; Physiology; Prospective Studies; Regression analysis; Risk factors; Sepsis; Severity of Illness Index; Systemic Inflammatory Response Syndrome - drug therapy; Systemic Inflammatory Response Syndrome - microbiology; Systemic Inflammatory Response Syndrome - mortality
• ISSN: 0934-9723; 1435-4373
• DOI: 10.1007/s10096-015-2527-2

The incidence of Candida bloodstream infections (BSIs) has increased over time, especially in medical wards. The objective of this study was to evaluate the impact of different antifungal treatment strategies on 30-day mortality in patients with Candida BSI not admitted to intensive care units (ICUs) at disease onset. This prospective, monocentric, cohort study was conducted at an 1100-bed university hospital in Rome, Italy, where an infectious disease consultation team was implemented. All cases of Candida BSIs observed in adult patients from November 2012 to April 2014 were included. Patients were grouped according to the initial antifungal strategy: fluconazole, echinocandin, or liposomal amphotericin B. Cox regression analysis was used to identify risk factors significantly associated with 15-day and 30-day mortality. During the study period, 130 patients with candidemia were observed (58 % with C. albicans , 7 % with C. glabrata , and 23 % with C. parapsilosis ). The first antifungal drug was fluconazole for 40 % of patients, echinocandin for 57.0 %, and liposomal amphotericin B for 4 %. During follow-up, 33 % of patients died. The cumulative mortality 30 days after the candidemia episode was 30.8 % and was similar among groups. In the Cox regression analysis, clinical presentation was the only independent factor associated with 15-day mortality, and Acute Physiology and Chronic Health Evaluation (APACHE) II score and clinical presentation were the independent factors associated with 30-day mortality. No differences in 15-day and 30-day mortality were observed between patients with and without C. albicans candidemia. In patients with candidemia admitted to medical or surgical wards, clinical severity but not the initial antifungal strategy were significantly correlated with mortality.